Please Enable Cookies

www.laserfocusworld.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Science 37 to Present at the 5ᵗʰ Annual Evercore ISI HealthCONx Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Science 37® Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the company will be participating in the upcoming 5th Annual Evercore ISI HealthCONx Conference.

Science 37’s management is scheduled to participate virtually in a fireside chat on Thursday, December 1, 2022, at 8:50 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investor Relations” section of the company’s website at: https://investors.science37.com.

About Science 37
Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 l Operating System (OS) supports today’s more agile clinical research designs with its full stack, end-to-end technology platform and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the Science 37 OS enables up to 21x faster enrollment, 28% better retention and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation and data harmonization. For more information, visit https://www.science37.com.

MEDIA INQUIRIES:
Grazia Mohren Science 37
Email: pr@science37.com

INVESTOR RELATIONS:
Steven Halper
LifeSci Advisors
Investors@science37.com


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.